参考文献/References:
[1] 唐 平,魏 兵,杨雯娟,等.乳腺癌预后/预测因子[J].中华病理学杂志,2011,40(2):73-76.
Tang P,Wei B,Yang WJ,et al.Prgnostic factors of breast cancer[J].Chinese Journal of Pathology,2011,40(2):73-76.
[2] Ravdin PM,Siminoff LA,Davis GJ,et al.Computer program to assist inmaking decisions about adjuvant therapy for women with early breast cancer[J].JClin Oneol,200l,19(4):980-991.
[3] Goldhirsch A,Ingle JN,Gelber RD,et al.Thresholds for therapies:highlights of the St Gallen International Expert Consensus on the primary therapy ofearly breast cancer 2009[J].Ann Oncol,2009,20(8):1319-1329.
[4] Carey LA.Through a glass darkly:advances in understanding breast cancer biology,2000~2010[J].Clin Breast Cancer,2010,10(3):188-195.
[5] Jatoi I,Anderson WF,Rosenberg PS.Qualitative age-interactions in breast cancer:a tale of two diseases?[J].Am J Clin Oncol,2008,31(5):504-506.
[6] Figueroa-Magalhaes MC,Jelovac D,Connolly RM,et al.Treatment of HER2-positive breast cancer[J].Current Treatment Options in Oncology,2014,23(2):128-136.
[7] Nishimura R,Osako T,Okumura Y,et al.Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer[J].Exp Ther Med,2010,1(5),747-754.
[8] Patnayak R,Jena A,Rukmangadha N,et al.Hormone receptor status(estrogen receptor,progesterone receptor),human epidermal growth factor-2 and p53 inSouth Indian breast cancer patients:A tertiary care center experience[J].Indian J Med Paediatr Onco,2015,36(2),117-122.
[9] Wolff AC,Hammond ME,Schwartz JN,el al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].Arch Pathol Lab Med,2007,1(1):1843.
[10] Hammond ME,Hayes DF,Dowsett M.et al.American society of Clinical Onology/College of American Pathologists guideline recommendations forimmunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].Arch Pathol Lab Med,2010,134(6):907-922.
[11] 《乳腺癌HER2检测指南(2009版)》编写组.乳腺癌HER2检测指南(2009版)[J].中华病理学杂志,2009,38(12):836-840.
相似文献/References:
[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis
Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2
和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2
and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
[3]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T
Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(05):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[4]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level
in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(05):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[5]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell
s[J].Journal of Modern Laboratory Medicine,2017,32(05):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[6]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A
>T(rs290987)Single Nucleotide Polymorphisms with Susceptibility
to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(05):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating
Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[8]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[9]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
[10]王承霞,朱玉蓉.乳腺癌患者血清中 tRF-32-Q99P9P9NH57SJ的表达及临床意义[J].现代检验医学杂志,2019,34(06):16.[doi:10.3969 / j.issn.1671-7414.2019.06.004]
WANG Cheng-xia,ZHU Yu-rong.Expression and Clinical Significance of tRF-32-Q99P9P9NH57SJ in Serum
of Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):16.[doi:10.3969 / j.issn.1671-7414.2019.06.004]